Review of NICE Technology Appraisal Guidance No. 278; Omalizumab for the treatment of severe persistent allergic asthma

Proposal to move the existing guidance to the static list 

The planned date for review of the above guidance is March 2016.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

Whilst there have been a number of new studies - and three systematic reviews published, there is no new evidence to suggest that the existing recommendations should be updated.

Consequently we propose that TA278 should move to the ‘static list’ of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.

Please see appendix A for a full list of the organisations we have contacted. 

March 2016

This page was last updated: